Challenges in the Therapy of Chromoblastomycosis

Date
2013-06-01Author
Queiroz-Telles, Flavio
Santos, Daniel Wagner de C. L. [UNIFESP]
Type
ArtigoISSN
0301-486XIs part of
MycopathologiaDOI
10.1007/s11046-013-9648-xMetadata
Show full item recordAbstract
Chromoblastomycosis (CBM) is an implantation mycosis mainly occurring in tropical and subtropical zones worldwide. If not diagnosed at early stages, patients with CBM require long-term therapy with systemic antifungals flanked by various physical treatment regimens. As in other neglected endemic mycoses, comparative clinical trials have not been performed for this disease; nowadays, therapy is mainly based on a few open trials and on expert opinions. Itraconazole, either as monotherapy or associated with other drugs, or with physical methods, is widely used. Recently, photodynamic therapy has been employed successfully in combination with antifungals in patients presenting with CBM. in the present paper, the most used therapeutic options against CBM are reviewed as well as the several factors that may have impact on the patient's outcome.
Citation
Mycopathologia. Dordrecht: Springer, v. 175, n. 5-6, p. 477-488, 2013.Keywords
Implantation mycosesSubcutaneous mycoses
Chromomycosis
Black fungi
Melanized fungi
Dematiaceous
Fonsecaea sp.
Cladophialophora sp.
Verrucous
Muriform
Sclerotic
Antifungals
Itraconazole
Posaconazole
Terbinafine
Photodynamic therapy
Collections
- EPM - Artigos [17701]